Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT01722513

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01722513
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01722513. Allocation not applicable; single masking; primary purpose prevention. Start 2012-11 (registry gives no type); primary completion 2013-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
Condition
Kidney Diseases
Condition
Diabetes Mellitus
Condition
Kidney Failure, Chronic
Condition
Renal Insufficiency
Intervention (Drug)
Alprostadil ﹠control
Lead sponsor
Shanghai 10th People's Hospital (class: other)

Record details

Record id
cardio:ct-nct01722513
Content hash
2d8dc3bbd656b32e580c9bf97bfcfa07c9e3103a3565d5b44f7b7db391e659a6